The potential rescheduling of cannabinoids, particularly at the federal level, is generating considerable excitement within the sector. A shift away from Schedule I status, often regarded as outdated and hindering advancement, could unlock significant avenues for companies. Reduced regulatory burdens, alongside greater access to banking and funding